北京阳光诺和药物研究股份有限公司是科创板上市企业（688621），是专注于仿制和创新药物研究，致力于以技术服务为核心，推动中国医药行业发展，为客户提供「临床前＋临床+CDMO」全过程药物研发服务的综合型CRO公司。阳光诺和从药物发现、到药理药效、药学研究，再到临床研究资源的整合，生物样本检测团队的构建，生产制造能力的整合，成功打造了全过程CRO服务模式。

Beijing Sun-novo Pharmaceutical Research Co., Ltd. is a listed company on the Science and Technology Innovation Board (688621). Focusing on generic and innovative drug research, it is a comprehensive CRO company committed to providing technological services, endeavoring to promote China’s pharmaceutical industry. From drug discovery, pharmacological and pharmaceutical research, to the integration of clinical research resources, biological sample testing and manufacturing capabilities, Sun-novo delivers "preclinical+clinical+CDMO" drug R&D services and a whole-process CRO model.

公司主营业务涵盖药理药效、临床研究、CDMO、创新药开发、仿制药开发及一致性评价的综合研发服务，服务内容主要包括药物发现、药理药效、药学研究、临床研究和生物分析。可进行完整的化学药研发、仿制药一致性评价、药物代谢分析与评价研究、多肽药物研发、临床生物等效性试验、药物Ⅰ-Ⅳ期临床研究、生物样品检测、注册申报（国内和进口）、国际合作等服务。

As a one-stop-shop with integrated services and technologies, Sun-novo serves from drug discovery, potency testing, biological analysis, clinical research, to CDMO, innovative drug development, generic drug development and consistency evaluation. It’s also equipped with strong expertise to conduct whole-process chemical drug and peptide drug R&D, generic drug consistency evaluation, metabolism analysis, clinical bioequivalence trials, phase I-IV clinical studies, biological sample testing, as well as drug registration and application (domestic and imported) for international cooperation.